Total Voting Rights

RNS Number : 5093R

Ergomed plc

01 March 2019

 

PRESS RELEASE

   FOR IMMEDIATE RELEASE

Total Voting Rights

Guildford, UK - 1 March 2019: In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules (DTRs), Ergomed plc (the "Company") announces the following information.

The Company's issued share capital as at 28 February 2019 consisted of 46,141,438 ordinary shares of 1p each, none of which were held in treasury.  Each ordinary share in the capital of the Company carries one voting right. 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.

- Ends -

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanovic (Executive Chairman)
Stuart Jackson (Chief Financial Officer)
Numis Securities Limited	Tel: [phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Joint Broker)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Mary-Jane Elliott	[e-mail]
Matthew Neal / Olivia Manser
MC Services - for Continental European enquiries	Tel: [phone]
Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

 

END

 

 

TVRTPMRTMBATBJL